You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科(06622.HK)發表治療乾眼症藥物臨床試驗結果
阿思達克 11-01 09:20
兆科眼科(06622.HK)公布,於上周五(10月29日)在中國上海舉行的第七屆全國乾眼學術會議上,公司發表環孢素A眼凝膠(公司主要候選藥物之一)用於治療乾眼症的關鍵第III期臨床試驗(COSMO)的完整結果。 研究涉及41個臨床試驗中心,自2020年12月起招募合共644名患者入組,招募工作於今年4月中提早兩個月完成。使用環孢素A眼凝膠治療與使用安慰劑治療的患者於治療期間出現的突發不良反應相近,患者回報的最常見副作用為眼痛,佔全部患者的8.2%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account